Stay updated on Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial

Sign up to get notified when there's something new on the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The page revision updated from v3.2.0 to v3.3.2, indicating a minor update to the study record. This change does not modify the study details or enrollment information.
    Difference
    0.0%
    Check dated 2025-11-25T11:52:32.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The government funding and operating status notice was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-11-18T07:14:33.000Z thumbnail image
  4. Check
    34 days ago
    Change Detected
    Summary
    No additions or deletions were detected on the page; the content appears unchanged between versions.
    Difference
    0.4%
    Check dated 2025-11-03T21:24:33.000Z thumbnail image
  5. Check
    62 days ago
    Change Detected
    Summary
    Major update: operating-status notice and new version v3.2.0; old v3.1.0 reference removed.
    Difference
    4%
    Check dated 2025-10-06T05:52:13.000Z thumbnail image
  6. Check
    69 days ago
    Change Detected
    Summary
    Version updated from v3.0.2 to v3.1.0; no other content changes detected.
    Difference
    0.1%
    Check dated 2025-09-29T03:10:23.000Z thumbnail image
  7. Check
    84 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.0.2, replacing v3.0.1. The 'Back to Top' link was removed.
    Difference
    0.2%
    Check dated 2025-09-14T19:18:41.000Z thumbnail image

Stay in the know with updates to Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page.